Clin Infect Dis. 2022 Sep 5:ciac735. doi: 10.1093/cid/ciac735. Online ahead of print.
OBJECTIVE: To compare clinical characteristics and outcomes of bloodstream infections (BSI) caused by Candida auris and other Candida spp.
METHODS: Multicenter, retrospective, case-control study at three hospitals in Brooklyn, New York between 2016 and 2020. Patients ≥18 years of age with a positive blood culture for any Candida spp. treated empirically with an echinocandin were included in the analysis. The primary outcome was 30-day mortality. Secondary outcomes were 14-day clinical failure, 90-day mortality, 60-day microbiologic recurrence, and in-hospital mortality.
RESULTS: 196 patients were included in the final analysis including 83 cases of candidemia caused by C. auris. After inverse propensity adjustment, C. auris BSI was not associated with increased odds of 30-day mortality (aOR 1.014 (0.563-1.828), p = 0.963) or 90-day mortality (aOR 0.863 (0.478-1.558), p = 0.625). A higher risk for microbiologic recurrence within 60 days of completion of antifungal therapy was observed in C. auris patients (aOR 4.461 (1.033-19.263), p = 0.045).
CONCLUSIONS: Candida auris BSI is not associated with an increased risk of mortality compared to BSI caused by other Candida spp. A higher risk for microbiologic recurrence occurred in the C. auris group.
PMID:36062367 | DOI:10.1093/cid/ciac735